Overview
BRAF assays detect activating mutations, most frequently V600E, using PCR or NGS methods on tumor DNA.
Clinical Importance
Select BRAF/MEK inhibitor pathways in melanoma and other approved indications
Prognostic/therapeutic stratification in colorectal cancer with RAS testing
Specimen Requirements
- Specimen: formalin-fixed paraffin-embedded (FFPE) tissue, fresh/frozen tissue, or cytology material as validated
- Tumor content: pathologist assessment of neoplastic cellularity often required before testing
- Handling: minimize fixation delays and harsh acid decalcification that damage nucleic acids
- Input: provide adequate tissue; microdissection may be used to enrich tumor
Analytical Method
Allele-specific PCR or NGS identifies BRAF V600 and other validated variants. IHC for BRAF V600E exists in some tumors as a screening adjunct but molecular confirmation policies vary.
Instruments Used
Automated analyzers
- Applied Biosystems / Thermo Fisher real-time PCR systems (e.g., QuantStudio-class)
- Roche Cobas molecular / LightCycler systems
- Cepheid GeneXpert cartridge PCR systems
- BioFire FilmArray syndromic PCR systems
- Illumina next-generation sequencing platforms
- Thermo Fisher Ion Torrent sequencing platforms
- Digital PCR systems (e.g., Bio-Rad QX / QIAGEN QIAcuity-class)
- Specialized BCR-ABL quantitative PCR systems / kits
Manual methods
- Manual RNA/DNA extraction with real-time PCR or sequencing workflows
Reference Values
Molecular cutoffs, units (IU/mL, copies/mL, Ct), reportable ranges, and variant classifications are assay- and laboratory-specific. Always interpret against the performing laboratory report, manufacturer IFU, and current CLSI / CAP / AMP / ACMG guidance as adopted locally. Limit of detection and inhibition controls are essential for negative results.
Mutation not detected / detected (variant specified). Drug eligibility follows oncology guidelines and labels.
Interpretation
Common Causes of Increased Results
- BRAF V600 mutation detected; supports targeted therapy pathways when clinically indicated
Common Causes of Decreased Results
- No BRAF V600 in covered regions; other drivers may still be present
Clinical Significance
- Melanoma molecular profiling
- CRC and other solid tumor panels
- Hairy cell leukemia supportive testing
Factors Affecting Results
Pre-analytical
- Wrong specimen type or transport medium for the validated assay
- Delayed transport degrading RNA targets
- Contamination during collection (especially amplicon-rich environments)
- Inadequate volume or low cellularity/tumor content
Analytical
- PCR inhibition (heparin, humic acids, excess hemoglobin; assay-dependent)
- Extraction failure or pipetting/contamination in amplification areas
- Probe/primer mismatch with sequence variants causing false negatives
- Calibration/QC failure; expired reagents
Post-analytical
- Reporting Ct or raw copies without assay-specific interpretive rules
- Misapplying another laboratory’s LOD or units
- Variant classification without current ACMG/AMP framework when required
Advantages and Limitations
Advantages
- Directly actionable in multiple tumor types
Limitations
- Non-V600 variants need appropriate panel coverage
- Tumor-type context changes therapy meaning
Clinical Pearls
BRAF V600E in melanoma and BRAF V600E in colorectal cancer are not the same therapeutic conversation.
References
Authoritative textbooks, guidelines, and reviews supporting this laboratory test reference. Verify reference intervals, critical limits, and method details against institutional protocols and current guideline editions.
Textbooks
- McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021. (Molecular diagnostics chapters, verify current edition.)
- Buckingham L. Molecular Diagnostics: Fundamentals, Methods, and Clinical Applications. 3rd ed. F.A. Davis; 2019. (Verify current edition and institutional adoption.)
CLSI and Professional Guidelines
- Clinical and Laboratory Standards Institute (CLSI). Consult current CLSI molecular method documents available through your laboratory, document numbers and editions change; do not treat any single CLSI title as universal.
- Institutional molecular laboratory standard operating procedures (SOPs), assay manufacturer instructions for use (IFU), and locally adopted accreditation requirements. Always verify current local practice.
- Clinical and Laboratory Standards Institute (CLSI). Molecular method evaluation and related documents (verify current CLSI editions applicable to the assay).
- College of American Pathologists. Molecular pathology accreditation and proficiency testing expectations (verify current CAP checklist requirements).
- Association for Molecular Pathology (AMP). Practice guidelines and position statements for molecular diagnostics (verify current AMP documents for the assay).
- American College of Medical Genetics and Genomics (ACMG). Standards and guidelines for interpretation of sequence variants and related genetic testing practice (verify current ACMG documents).
WHO Publications
- World Health Organization. Laboratory and diagnostic guidance relevant to molecular testing (verify current WHO publication for the assay/pathogen).
Frequently Asked Questions
Common questions about using this BRAF Mutation laboratory test Medical Laboratory Library reference in Medical Laboratory Science education.
What is the BRAF Mutation laboratory test reference used for?
This Medical Laboratory Library page summarizes the clinical importance of BRAF Mutation. Review the Clinical Importance section for why the test is ordered in laboratory medicine practice.
Where can I find BRAF Mutation specimen requirements?
See the Specimen Requirements section on this page for specimen information related to BRAF Mutation. Confirm collection details against your laboratory protocol.
Where are BRAF Mutation reference values listed?
See the Reference Values section on this Laboratory Library page. Reference ranges can vary by method and population, so verify intervals with your laboratory.
How do I interpret BRAF Mutation results?
Use the Interpretation section for laboratory interpretation framing, including increased and decreased result patterns when provided. Do not treat educational text as a patient-specific diagnosis.
What analytical method is used for BRAF Mutation?
See the Analytical Method section for principle and method notes. Method details may differ by instrument and institutional SOP.
Are related laboratory tests linked from BRAF Mutation?
Yes. The Related Laboratory Tests section lists connected references for continued lookup in the Medical Laboratory Library.
How can I continue learning after reading BRAF Mutation?
Use Continue learning links on this page for related Academy lessons, medical laboratory quizzes, or laboratory case studies when available for this Molecular Diagnostics topic.
What are the clinical pearls for BRAF Mutation?
See the Clinical Pearls section for concise laboratory practice notes associated with BRAF Mutation. Apply pearls alongside institutional protocols.
Reading progress
Awards XP once after you have meaningfully reviewed this article.